-+ 0.00%
-+ 0.00%
-+ 0.00%

Addex GABAB PAM candidate cuts cough in bleomycin IPF-related chronic cough model

PUBT·04/29/2026 05:00:48
Listen to the news
Addex GABAB PAM candidate cuts cough in bleomycin IPF-related chronic cough model
  • Addex Therapeutics on April 29, 2026 reported new preclinical results for its GABAB positive allosteric modulator candidate in a bleomycin-induced idiopathic pulmonary fibrosis-related chronic cough model.
  • Data were presented as already generated, with no future presentation disclosed.
  • Study showed sustained cough suppression over chronic dosing, supporting potential use in chronic cough management.
  • Results also indicated improvements in disease-related lung outcomes versus untreated animals, suggesting possible added benefit beyond symptom control.
  • Safety observations remained favorable in the model, reinforcing the compound’s positioning for longer-term development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290100PRIMZONEFULLFEED1001178541) on April 29, 2026, and is solely responsible for the information contained therein.